PlainPill

LGD-4033 vs MK-2866 for performance

Short answer: For performance, users rate them about the same: 90% report improvement with LGD-4033 (226 reports) and 87% with MK-2866 (252 reports).

LGD-4033 has 1 meta-analyses and 1 randomized trials on PubMed; MK-2866 has 0 and 0.

Based on 630 reports about LGD-4033 and 789 about MK-2866. Not medical advice.

LGD-4033
SARM
MK-2866
SARM
Users say it helped48%helped353 reports · high confidence37%helped489 reports · high confidence
Verdict
Mixed
Mixed
ResearchBResearch: ModerateDResearch: None
Meta-analyses / RCTs1 / 10 / 0
Mainly used for
Performance
% reporting improvement
90% (226)87% (252)
Hormones
% reporting improvement
4% (54)3% (100)
Weight loss
% reporting improvement
82% (45)88% (100)
Mood
% reporting improvement
23% (30)66% (64)
Recovery
% reporting improvement
88% (16)96% (78)
Common side effectssuppression, water retention, fatigue, stomach issuessuppression, fatigue, insomnia, headache
Typical dose reportedNot listedNot listed
LGD-4033
Latest review conclusion

SARMs have a positive effect on physical performance and body composition and are associated with moderate rates of mild to moderate adverse effects (AEs) and a low rate of severe AEs.

Clin Endocrinol (Oxf), 2025 ↗
What a user said
“I've taken LDG-4033 and Ostarine from Ceretropic and noticed slight psychoactive effects from both, immediately (within 30 minutes after dosing).”
Full LGD-4033 profile →
MK-2866
What a user said
“I've taken LDG-4033 and Ostarine from Ceretropic and noticed slight psychoactive effects from both, immediately (within 30 minutes after dosing).”
Full MK-2866 profile →

Related comparisons

Percentages come from first-hand user reports and are not clinical outcomes. Talk to a doctor before starting, stopping or combining anything. How we rate